Researchers identify 4-gene signature to predict neonatal sepsis before symptoms

The study uncovers gene expression signatures that predict neonatal sepsis, highlighting the potential for early intervention to reduce mortality in infants.

Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for two more trials

Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored

May 14, 2024

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada. | Psychedelic Invest

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and

January 26, 2024

Risk Adjusted Net Present Value: What is the current valuation of HilleVax’s HIL-214

The revenue for HIL-214 is expected to reach an annual total of $24 mn by 2039 in the US based off GlobalDatas Expiry Model. The

September 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.